A phase 2 trial of R1507, a monoclonal antibody to the insulin‐like growth factor‐1 receptor (IGF‐1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study

Study protocol of regosarc trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase ii trial

Brodowicz, Thomas
Liegl-Atzwanger, Bernadette
Tresch-Bruneel, Emmanuelle
Taieb, Sophie
Kramar, Andrew
Gruenwald, Viktor
Vanseymortier, Marie
Clisant-Delaine, Stephanie
Blay, Jean-Yves
Le Cesne, Axel
Penel, Nicolas

March 2015

International audienceBACKGROUND: Angiogenesis, among other signaling pathways, plays a key-role in ...

Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial

Chugh, R.
Wathen, J. K.
Patel, S. R.
Maki, R. G.
Meyers, P. A.
Schuetze, S. M.
Priebat, D. A.
Thomas, D. G.
Jacobson, J. A.
Samuels, B. L.
Benjamin, R. S.
Baker, L. H.
Sarcoma Alliance for Research through, Collaboration

October 2010

PURPOSE: Aggressive fibromatoses (AF; desmoid tumors) are rare clonal neoplastic proliferations of c...

Insulin-Like Growth Factor 1 Receptor and Response to Anti-IGF1R Antibody Therapy in Osteosarcoma

Yu Cao
Michael Roth
Sajida Piperdi
Kristofer Montoya
Rebecca Sowers
Pulivarthi Rao
David Geller
Peter Houghton
E. Anders Kolb
Jonathan Gill
Richard Gorlick

November 2015

Background: Survival outcomes for patients with osteosarcoma (OS) have remained stagnant over the pa...

A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study

Pappo, A. S.
Vassal, G.
Crowley, J. J.
Bolejack, V.
Hogendoorn, P. C.
Chugh, R.
Ladanyi, M.
Grippo, J. F.
Dall, G.
Staddon, A. P.
Chawla, S. P.
Maki, R. G.
Araujo, D. M.
Geoerger, B.
Ganjoo, K.
Marina, N.
Blay, J. Y.
Schuetze, S. M.
Chow, W. A.
Helman, L. J.

August 2014

BACKGROUND: Insulin-like growth factor-1 receptor (IGF-1R) is implicated in the pathogenesis of rhab...

R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study

Pappo, A. S.
Patel, S. R.
Crowley, J.
Reinke, D. K.
Kuenkele, K. P.
Chawla, S. P.
Toner, G. C.
Maki, R. G.
Meyers, P. A.
Chugh, R.
Ganjoo, K. N.
Schuetze, S. M.
Juergens, H.
Leahy, M. G.
Geoerger, B.
Benjamin, R. S.
Helman, L. J.
Baker, L. H.

December 2011

PURPOSE: The type 1 insulin-like growth factor 1 receptor (IGF-1R) has been implicated in the pathog...

The insulin-like growth factor system and sarcomas.

Rikhof, B.
Jong, S. de
Suurmeijer, A.J.H.
Meijer, C.
Graaf, W.T.A. van der

January 2009

Contains fulltext : 81254.pdf (publisher's version ) (Closed access)Sarcomas are a...

Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02)

Lu Xie
Xin Liang
Jie Xu
Xin Sun
Kuisheng Liu
Kunkun Sun
Yuan Li
Xiaodong Tang
Xianan Li
Xing Zhan
Xiaohui Niu
Wei Guo

September 2023

Abstract Background Novel and effective immunotherapies are required for refractory or recurrent sar...

Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Childrens Oncology Group.

Hingorani, Pooja
Krailo, Mark
Buxton, Allen
Hutson, Paul
Sondel, Paul
Diccianni, Mitchell
Yu, Alice
Morris, Carol
Womer, Richard
Crompton, Brian
Teot, Lisa
DuBois, Steven
Janeway, Katherine
Gorlick, Richard
Isakoff, Michael
Randall, R

September 2022

PURPOSE: Novel effective therapies are urgently needed in recurrent osteosarcoma. GD2 is expressed i...

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

Schwartz, G. K.
Tap, W. D.
Qin, L. X.
Livingston, M. B.
Undevia, S. D.
Chmielowski, B.
Agulnik, M.
Schuetze, S. M.
Reed, D. R.
Okuno, S. H.
Ludwig, J. A.
Keedy, V.
Rietschel, P.
Kraft, A. S.
Adkins, D.
Van Tine, B. A.
Brockstein, B.
Yim, V.
Bitas, C.
Abdullah, A.
Antonescu, C. R.
Condy, M.
Dickson, M. A.
Vasudeva, S. D.
Ho, A. L.
Doyle, L. A.
Chen, H. X.
Maki, R. G.

April 2013

BACKGROUND: Preclinical studies have shown synergistic antitumour activity by inhibition of insulin-...

Articles Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

Gary K Schwartz
William D Tap
Li-xuan Qin
Michael B Livingston
Samir D Undevia
Bartosz Chmielowski
Mark Agulnik
Scott M Schuetze
Vincent Yim
Christiana Bitas
Abdul Abdullah
Cristina R Antonescu
Mercedes Condy
Mark A Dickson
Shyamprasad Deraje Vasudeva
Alan L Ho
L Austin Doyle
Helen X Chen
Robert G Maki

January 2013

Background Preclinical studies have shown synergistic antitumour activity by inhibition of insulin-l...

The insulin-like growth factor system and sarcomas

Rikhof, Bart
de Jong, Steven
Suurmeijer, Albert J. H.
Meijer, Coby
van der Graaf, Winette T. A.

March 2009

Sarcomas are a diverse group of malignant mesenchymal tumours arising from bone and soft tissues. Th...

Current and future treatment strategies for rhabdomyosarcoma

Chen, C.
Dorado-Garcia, H.
Scheer, M.
Henssen, A.G.

December 2019

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, and can be subcategorized...

Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside.

Olmos, D
Tan, DSW
Jones, RL
Judson, IR

May 2010

Two decades have elapsed since insulin-like growth factor-1 receptor (IGF-1R) signaling was initiall...

Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.

Asmane, Irène
Watkin, Emmanuel
Alberti, Laurent
Duc, Adeline
Marec-Berard, Perrine
Ray-Coquard, Isabelle
Cassier, Philippe
Decouvelaere, Anne-Valérie
Ranchère, Dominique
Kurtz, Jean-Emmanuel
Bergerat, Jean-Pierre
Blay, Jean-Yves

November 2012

International audienceAIMS: A minority of patients with advanced sarcoma achieve prolonged progressi...

R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts

Kolb, E. Anders
Kamara, Davida
Zhang, Wendong
Lin, Juan
Hingorani, Pooja
Baker, Laurence
Houghton, Peter
Gorlick, Richard

July 2010

Background The combination of rapamycin and R1507, a fully human IgG1 monoclonal antibody targeting...

Study protocol of regosarc trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase ii trial

Brodowicz, Thomas
Liegl-Atzwanger, Bernadette
Tresch-Bruneel, Emmanuelle
Taieb, Sophie
Kramar, Andrew
Gruenwald, Viktor
Vanseymortier, Marie
Clisant-Delaine, Stephanie
Blay, Jean-Yves
Le Cesne, Axel
Penel, Nicolas

March 2015

International audienceBACKGROUND: Angiogenesis, among other signaling pathways, plays a key-role in ...

Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial

Chugh, R.
Wathen, J. K.
Patel, S. R.
Maki, R. G.
Meyers, P. A.
Schuetze, S. M.
Priebat, D. A.
Thomas, D. G.
Jacobson, J. A.
Samuels, B. L.
Benjamin, R. S.
Baker, L. H.
Sarcoma Alliance for Research through, Collaboration

October 2010

PURPOSE: Aggressive fibromatoses (AF; desmoid tumors) are rare clonal neoplastic proliferations of c...

Insulin-Like Growth Factor 1 Receptor and Response to Anti-IGF1R Antibody Therapy in Osteosarcoma

Yu Cao
Michael Roth
Sajida Piperdi
Kristofer Montoya
Rebecca Sowers
Pulivarthi Rao
David Geller
Peter Houghton
E. Anders Kolb
Jonathan Gill
Richard Gorlick

November 2015

Background: Survival outcomes for patients with osteosarcoma (OS) have remained stagnant over the pa...

A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study

Pappo, A. S.
Vassal, G.
Crowley, J. J.
Bolejack, V.
Hogendoorn, P. C.
Chugh, R.
Ladanyi, M.
Grippo, J. F.
Dall, G.
Staddon, A. P.
Chawla, S. P.
Maki, R. G.
Araujo, D. M.
Geoerger, B.
Ganjoo, K.
Marina, N.
Blay, J. Y.
Schuetze, S. M.
Chow, W. A.
Helman, L. J.

August 2014

BACKGROUND: Insulin-like growth factor-1 receptor (IGF-1R) is implicated in the pathogenesis of rhab...

R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study

Pappo, A. S.
Patel, S. R.
Crowley, J.
Reinke, D. K.
Kuenkele, K. P.
Chawla, S. P.
Toner, G. C.
Maki, R. G.
Meyers, P. A.
Chugh, R.
Ganjoo, K. N.
Schuetze, S. M.
Juergens, H.
Leahy, M. G.
Geoerger, B.
Benjamin, R. S.
Helman, L. J.
Baker, L. H.

December 2011

PURPOSE: The type 1 insulin-like growth factor 1 receptor (IGF-1R) has been implicated in the pathog...

The insulin-like growth factor system and sarcomas.

Rikhof, B.
Jong, S. de
Suurmeijer, A.J.H.
Meijer, C.
Graaf, W.T.A. van der

January 2009

Contains fulltext : 81254.pdf (publisher's version ) (Closed access)Sarcomas are a...

Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02)

Lu Xie
Xin Liang
Jie Xu
Xin Sun
Kuisheng Liu
Kunkun Sun
Yuan Li
Xiaodong Tang
Xianan Li
Xing Zhan
Xiaohui Niu
Wei Guo

September 2023

Abstract Background Novel and effective immunotherapies are required for refractory or recurrent sar...

Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Childrens Oncology Group.

Hingorani, Pooja
Krailo, Mark
Buxton, Allen
Hutson, Paul
Sondel, Paul
Diccianni, Mitchell
Yu, Alice
Morris, Carol
Womer, Richard
Crompton, Brian
Teot, Lisa
DuBois, Steven
Janeway, Katherine
Gorlick, Richard
Isakoff, Michael
Randall, R

September 2022

PURPOSE: Novel effective therapies are urgently needed in recurrent osteosarcoma. GD2 is expressed i...

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

Schwartz, G. K.
Tap, W. D.
Qin, L. X.
Livingston, M. B.
Undevia, S. D.
Chmielowski, B.
Agulnik, M.
Schuetze, S. M.
Reed, D. R.
Okuno, S. H.
Ludwig, J. A.
Keedy, V.
Rietschel, P.
Kraft, A. S.
Adkins, D.
Van Tine, B. A.
Brockstein, B.
Yim, V.
Bitas, C.
Abdullah, A.
Antonescu, C. R.
Condy, M.
Dickson, M. A.
Vasudeva, S. D.
Ho, A. L.
Doyle, L. A.
Chen, H. X.
Maki, R. G.

April 2013

BACKGROUND: Preclinical studies have shown synergistic antitumour activity by inhibition of insulin-...

Articles Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

Gary K Schwartz
William D Tap
Li-xuan Qin
Michael B Livingston
Samir D Undevia
Bartosz Chmielowski
Mark Agulnik
Scott M Schuetze
Vincent Yim
Christiana Bitas
Abdul Abdullah
Cristina R Antonescu
Mercedes Condy
Mark A Dickson
Shyamprasad Deraje Vasudeva
Alan L Ho
L Austin Doyle
Helen X Chen
Robert G Maki

January 2013

Background Preclinical studies have shown synergistic antitumour activity by inhibition of insulin-l...

The insulin-like growth factor system and sarcomas

Rikhof, Bart
de Jong, Steven
Suurmeijer, Albert J. H.
Meijer, Coby
van der Graaf, Winette T. A.

March 2009

Sarcomas are a diverse group of malignant mesenchymal tumours arising from bone and soft tissues. Th...

Current and future treatment strategies for rhabdomyosarcoma

Chen, C.
Dorado-Garcia, H.
Scheer, M.
Henssen, A.G.

December 2019

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, and can be subcategorized...

Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside.

Olmos, D
Tan, DSW
Jones, RL
Judson, IR

May 2010

Two decades have elapsed since insulin-like growth factor-1 receptor (IGF-1R) signaling was initiall...

Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.

Asmane, Irène
Watkin, Emmanuel
Alberti, Laurent
Duc, Adeline
Marec-Berard, Perrine
Ray-Coquard, Isabelle
Cassier, Philippe
Decouvelaere, Anne-Valérie
Ranchère, Dominique
Kurtz, Jean-Emmanuel
Bergerat, Jean-Pierre
Blay, Jean-Yves

November 2012

International audienceAIMS: A minority of patients with advanced sarcoma achieve prolonged progressi...

R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts

Kolb, E. Anders
Kamara, Davida
Zhang, Wendong
Lin, Juan
Hingorani, Pooja
Baker, Laurence
Houghton, Peter
Gorlick, Richard

July 2010

Background The combination of rapamycin and R1507, a fully human IgG1 monoclonal antibody targeting...

Study protocol of regosarc trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase ii trial

Brodowicz, Thomas
Liegl-Atzwanger, Bernadette
Tresch-Bruneel, Emmanuelle
Taieb, Sophie
Kramar, Andrew
Gruenwald, Viktor
Vanseymortier, Marie
Clisant-Delaine, Stephanie
Blay, Jean-Yves
Le Cesne, Axel
Penel, Nicolas

March 2015

International audienceBACKGROUND: Angiogenesis, among other signaling pathways, plays a key-role in ...

Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial

Chugh, R.
Wathen, J. K.
Patel, S. R.
Maki, R. G.
Meyers, P. A.
Schuetze, S. M.
Priebat, D. A.
Thomas, D. G.
Jacobson, J. A.
Samuels, B. L.
Benjamin, R. S.
Baker, L. H.
Sarcoma Alliance for Research through, Collaboration

October 2010

PURPOSE: Aggressive fibromatoses (AF; desmoid tumors) are rare clonal neoplastic proliferations of c...

Insulin-Like Growth Factor 1 Receptor and Response to Anti-IGF1R Antibody Therapy in Osteosarcoma

Yu Cao
Michael Roth
Sajida Piperdi
Kristofer Montoya
Rebecca Sowers
Pulivarthi Rao
David Geller
Peter Houghton
E. Anders Kolb
Jonathan Gill
Richard Gorlick

November 2015

Background: Survival outcomes for patients with osteosarcoma (OS) have remained stagnant over the pa...

Abstract

Extracted data

Abstract

Extracted data

Related items

Related items